MAP4K4 inhibitors (Pfizer)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameMAP4K4 inhibitors (Pfizer)
Drug Alias NamePF-06745013PF-06279789
ClassificationSmall molecules
Mechanisms of ActionMitogen-activated protein kinase kinase kinase kinase 4 inhibitorsAnticancer protein kinase inhibitors
TargetsMitogen-activated protein kinase kinase kinase kinase 4
Therapy Area/IndicationsNerve DegenerationDiabetes MellitusHeart Failure +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsNerve DegenerationDiabetes MellitusHeart Failure +[4] 

Other Information

ATC CodeN/A
Related LinksN/A